How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,430 results for

Constipation in Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Systematic review of interventions for the prevention and treatment of constipation in adult patients with cancer, including opioid-induced constipation and general constipation

Systematic review of interventions for the prevention and treatment of constipation in adult patients with cancer, including opioid-induced constipation and general constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

2. Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines

Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines † P. J. Larkin 1,2 , N. I. Cherny 3 , D. La Carpia 4 , M. Guglielmo 5 , C. Ostgathe 6 , F. Scotte ´ 7 & C. I. Ripamonti 5 ,on behalf of the ESMO Guidelines Committee * 1 School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin; 2 (...) by the patient and diagnostic criteria do not always clearly ex- press the diversity of factors, which may lead to constipation as a clinical problem [2]. Widespread use of opioid analgesics for cancer pain poses speci?c challenges for patients [3]. Despite its clinical im- pact, constipation is both poorly recognised and poorly treated. Oncologists must be familiar with the common causes of constipa- tion among cancer patients and the strategies to evaluate and man- age this distressing symptom

2018 European Society for Medical Oncology

3. Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines

in patients with a blocked or perforated bowel or patients at high risk of bowel blockage. For the full list of side effects and restrictions, see the package leaflet. Why is Rizmoic authorised in the EU? Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition. Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain). Furthermore, the side (...) Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/21684/2019 EMEA/H/C/004256 Rizmoic An overview of Rizmoic and why it is authorised in the EU

2019 European Medicines Agency - EPARs

4. Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis

Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

5. Constipation

% of people with cancer will require treatment with laxatives at some time. People receiving palliative care have multiple (...) causes of constipation , such as: Drugs, for example, opioid analgesics, antimuscarinic drugs, antacids. Secondary effects of disease, for example, dehydration, inadequate dietary fibre, inactivity, delirium, spinal cord compression, lack of privacy. Direct effects of malignant tumours, causing bowel obstruction, hypercalcaemia, nerve damage. When assessing a person (...) Constipation Top results for constipation - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2

2018 Trip Latest and Greatest

6. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation

| | | Constipation is by far the most common and debilitating gastrointestinal effect of opioids, and some degree of constipation is near universal in patients taking opioid medications. x 11 Bell, T.J., Panchal, S.J., Miaskowski, C. et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med . 2009 ; 10 : 35–42 | | | , x 12 Sykes, N.P. The relationship between opioid use and laxative use in terminally ill cancer patients (...) . 2009 ; 10 : 35–42 | | | , x 15 Abramowitz, L., Beziaud, N., Labreze, L. et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ . 2013 ; 16 : 1423–1433 | | | , x 16 Kalso, E., Edwards, J.E., Moore, R.A. et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain . 2004 ; 112 : 372–380 | | | | | OIC by definition is a condition associated

2019 American Gastroenterological Association Institute

7. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized (...) , double-blind, placebo-controlled study (COMPOSE-4) and an open-label, 12-week extension study (COMPOSE-5). In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned on a 1:1 basis to receive once-daily oral naldemedine 0.2 mg or placebo. The primary end point was the proportion of spontaneous bowel movement (SBM) responders (≥ 3 SBMs/week and an increase of ≥ 1 SBM/week from baseline). The primary end point of COMPOSE-5 was safety. Results In COMPOSE-4, 193 eligible patients were

2017 EvidenceUpdates

8. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer Purpose This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer and opioid-induced constipation. Methods Patients ≥ 18 years old (...) with cancer, an Eastern Cooperative Oncology Group performance status ≤ 2, who had been receiving a stable regimen of opioid analgesics for ≥ 2 weeks, had at least one constipation symptom despite laxative use, and no more than five spontaneous bowel movements (SBMs) during the past 14 days, were randomly assigned (1:1:1:1) to oral, once-daily naldemedine 0.1, 0.2, or 0.4 mg, or placebo, for 14 days. The primary end point was change in SBM frequency per week from baseline during the treatment period

2017 EvidenceUpdates

9. Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia. (PubMed)

Hong Kong Chinese Medicine Clinical Practice Guideline for Cancer Palliative Care: Pain, Constipation, and Insomnia. It is common for patients with cancers in Hong Kong seeking Chinese Medicine (CM) therapies as supportive care during cancer treatment and to manage treatment-related side effects. This article provides clinical practice guideline (CPG) on the use of CM for specific clinical indications caused by cancer and during cancer treatment, including pain, constipation, and insomnia

Full Text available with Trip Pro

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

10. Constipation in older adults: Stepwise approach to keep things moving

for alarm features ( ) that require additional investigations to rule out structural diseases (eg, colon cancer). , Mrs N.M. does not have any alarm features. Box 2. Alarm features of constipation Most important questions to ask your patient: Have you had any fever, had unintentional weight loss, had blood in or on your stool, felt any masses (abdominal or rectal), had night symptoms, or had any other unexplained symptoms? Are you vomiting? Do you have a lot of abdominal pain? Are you still passing gas (...) ? Do you have a family history of colon cancer or inflammatory bowel disease? Other alarm features: Age older than 50 y with recent onset of symptoms Abnormal laboratory bloodwork results (eg, anemia or iron deficiency) Step 3: Identify and treat reversible causes A number of diseases and conditions have been suspected of causing constipation ( ). , , Optimizing the management of these diseases, when possible, should be attempted in an effort to lessen or resolve the constipation. However

2016 RxFiles

11. Constipation

Constipation Constipation | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Constipation is defined as the decreased passage of stool characterized by infrequent bowel movements, hard stool, sensation of abdominal bloating or cramping, straining with bowel movements, and feeling of incomplete evacuation. Constipation can be a symptom of the cancer itself because of pressure that can partially or totally occlude the bowel. Constipation also can occur because (...) of problems of immobility or dehydration as a result of cancer treatment that directly affects the bowel or innervation of the gastrointestinal tract and as a result of medication. Opioid-induced constipation is a problem in patients who require opioids for pain management. The incidence of constipation among patients with cancer has not been well defined. In the palliative care population, prevalence of 40%–64% has been reported, and the symptom can be as high as 70%–100% among hospitalized patients

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

12. Effect of auricular points treatment combined with acupoints application in patients with constipation after lung cancer surgery. (PubMed)

Effect of auricular points treatment combined with acupoints application in patients with constipation after lung cancer surgery. To assess the effect of auricular points treatment combined with acupoints application on patient with constipation after lung cancer surgery.Design and participants: This is a single-center randomized controlled trial. Totally 341 after lung cancer surgery patients were randomly assigned into the experimental group (n = 174) and the control group (n = 167 (...) of constipation in the control group was higher than that in the experimental group (P < 0.001). Moreover, the stool characteristics of experimental group were better than it in the control group by rank-sum test (P = 0.047).On the basis of routine measures to prevent constipation after lung cancer surgery, auricular point sticking combined with acupoint application therapy can effectively decrease the incidence of postoperative constipation.

Full Text available with Trip Pro

2018 Journal of cancer research and therapeutics

13. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. (PubMed)

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. 29406801 2018 03 28 1527-7755 36 10 2018 Apr 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. 1049-1050 10.1200/JCO.2017.76.9349 Yagi Yukako Y Yukako Yagi and Kazuhiro Kosugi, National Cancer Center (...) Hospital East, Chiba, Japan; and Tetsuya Tanimoto, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan. Kosugi Kazuhiro K Yukako Yagi and Kazuhiro Kosugi, National Cancer Center Hospital East, Chiba, Japan; and Tetsuya Tanimoto, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan. Tanimoto Tetsuya T Yukako Yagi and Kazuhiro Kosugi, National Cancer Center Hospital East, Chiba, Japan; and Tetsuya Tanimoto, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan. eng Journal Article 2018 02 06 United

2018 Journal of clinical oncology : official journal of the American Society of Clinical Oncology

14. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. (PubMed)

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. The long-term safety of naldemedine, a peripherally acting µ-opioid receptor antagonist, was evaluated in patients with opioid-induced constipation and chronic noncancer pain in a 52-week, randomized, double-blind, phase 3 study. Eligible adults who could be on a routine laxative regimen were randomized 1:1 (...) to receive once-daily oral naldemedine 0.2 mg (n = 623) or placebo (n = 623). The primary endpoint was summary measures of treatment-emergent adverse events (AEs). Additional endpoints included opioid withdrawal on the Clinical Opiate Withdrawal Scale and the Subjective Opiate Withdrawal Scale, pain intensity on Numeric Rating Scale, frequency of bowel movements, and constipation-related symptoms and quality of life on the Patient Assessment of Constipation Symptoms and Patient Assessment of Constipation

Full Text available with Trip Pro

2018 Pain

15. Chinese herbal medicine for opioid induced constipation in cancer patients: Protocol for a systematic review. (PubMed)

Chinese herbal medicine for opioid induced constipation in cancer patients: Protocol for a systematic review. Opioid induced constipation (OIC) is a symptom that is commonly encountered in cancer pain management. Chinese herbal medicine (CHM) has been widely used to improve OIC in China. Many clinical trials indicate that CHM could improve OIC. In this systematic review, we aim to evaluate the effectiveness and safety of CHM for OIC in cancer patients.We will search the following electronic (...) databases for randomized controlled trials to evaluate the effectiveness and safety of CHM for OIC in cancer patients: CENTRAL, EMBASE, MEDILINE, CINAHL and China National Knowledge Infrastructure. Each database will be searched from inception to June 2018. The entire process will include study selection, data extraction, risk of bias assessment and meta-analyses.This proposed study will evaluate the effectiveness and safety of CHM for OIC. The outcomes will include change in bowel movements, quality

Full Text available with Trip Pro

2018 Medicine

16. Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain

Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2018 Clinical Trials

17. Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. (PubMed)

Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. The efficacy and safety of naldemedine (a peripherally-acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase 3, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary endpoint, the proportion of spontaneous bowel (...) movement (SBM) responders, was met. Here, we report results from secondary endpoints including quality of life (QOL) assessments from these studies.In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned 1:1 to receive once-daily oral naldemedine 0.2 mg (n=97) or placebo (n=96) for 2 weeks, and those who continued on to COMPOSE-5 received naldemedine for 12 weeks (n=131). Secondary assessments in COMPOSE-4 included the proportion of complete SBM (CSBM) responders, SBM or CSBM

Full Text available with Trip Pro

2018 Annals of Oncology

18. Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. (PubMed)

Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. Since 1966 when the Cystic Fibrosis Foundation Patient Registry (CFFPR) was founded, clinicians have witnessed significant advances in both the quality and quantity of life for patients living with Cystic Fibrosis (CF). As patients with CF live longer and fuller lives, increasing encumbrances from gastrointestinal manifestations of CF will be observed. This article serves to discuss "below (...) the diaphragm" concerns involving the large intestine (Distal Intestinal Obstruction Syndrome, Constipation, and Colorectal Cancer). Avenues for development and implementation of clinical care protocols, particularly regarding proactive management of known associated conditions and cancer screening, will continue to be refined in the coming years. It falls to the multidisciplinary CF care team to be actively engaged in addressing these concerns effectively as priority shifts from relative acuity (typically

2017 Journal of Cystic Fibrosis

19. The Efficacy and Safety of Transcutaneous Acupoint Interferential Current Stimulation for Cancer Pain Patients With Opioid-Induced Constipation: A Prospective Randomized Controlled Study (PubMed)

The Efficacy and Safety of Transcutaneous Acupoint Interferential Current Stimulation for Cancer Pain Patients With Opioid-Induced Constipation: A Prospective Randomized Controlled Study Opioid-induced constipation (OIC) is a principal complication secondary to analgesic therapy for cancer pain patients who suffer moderate to severe pain. In this study, we observe the efficacy and safety of transcutaneous acupoint interferential current (IFC) stimulation in those patients with OIC.A total (...) , P = .041, P = .011, respectively).Transcutaneous acupoint IFC therapy over acupoints of Tianshu (ST25) and Zhongwan (RN12) may improve constipation and quality of life in cancer patients receiving opiates; further studies are worthwhile.

Full Text available with Trip Pro

2017 Integrative cancer therapies

20. Managing Constipation in Adults With Cancer (PubMed)

Managing Constipation in Adults With Cancer Constipation is common in individuals with cancer, occurring in almost 60% of patients overall. The incidence increases in patients with advanced disease, particularly in those receiving opioid analgesics or medications with anticholinergic properties. Constipation is not uniformly assessed and therefore not recognized and appropriately managed in many instances. This can increase patients' physical and psychological distress. Furthermore (...) , there is scant research to support current management strategies for constipation. The objectives of this review are to explore the incidence of and risk factors for constipation in patients with cancer, to discuss the extent of the problem, to explore the nonpharmacologic and pharmacologic measures for constipation and fecal impaction, and to synthesize a laxative management. An extensive review of medical, pharmacy, and nursing literature was done to explore the physiology and pathogenesis of constipation

Full Text available with Trip Pro

2017 Journal of the advanced practitioner in oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>